` ENTA (Enanta Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

ENTA
vs
S&P 500

Over the past 12 months, ENTA has underperformed S&P 500, delivering a return of -54% compared to the S&P 500's 12% growth.

Stocks Performance
ENTA vs S&P 500

Loading

Performance Gap
ENTA vs S&P 500

Loading
ENTA
S&P 500
Difference

Performance By Year
ENTA vs S&P 500

Loading
ENTA
S&P 500
Add Stock

Competitors Performance
Enanta Pharmaceuticals Inc vs Peers

S&P 500
ENTA
ABBV
AMGN
GILD
VRTX
Add Stock

Enanta Pharmaceuticals Inc
Glance View

Market Cap
122.7m USD
Industry
Biotechnology

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2013-03-21. The firm is engaged in development of small molecule drugs for the treatment of viral infections and liver diseases. The firm has clinical candidates for the disease targets, including respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). The firm has discovered glecaprevir, a protease inhibitor discovered and developed for the treatment of chronic hepatitis C virus (HCV). Glecaprevir is co-formulated direct-acting antiviral (DAA), a combination treatment for HCV infection under the tradenames: MAVYRET and MAVIRET. Its product candidates also include EDP-514, EDP-305 and EDP-938. The firm's subsidiary is Enanta Pharmaceuticals Security Corporation.

ENTA Intrinsic Value
10.92 USD
Undervaluation 47%
Intrinsic Value
Price
Back to Top